Moderna (MRNA)

NASDAQ:MRNA

MRNA

Moderna

RESEARCH TOOLSreports

Moderna (MRNA) Stock Forecast & Price Target

18,013 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRNA Analyst Ratings

Hold

1 Buy

15 Hold

2 Sell

Based on 18 analysts giving stock ratings to

Moderna

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRNA Stock 12 Month Forecast

Average Price Target

$37.14

▼(-24.51% Downside)

Based on 18 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $37.14 with a high forecast of $69.00 and a low forecast of $12.00. The average price target represents a -24.51% change from the last price of $49.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","70":"$70","25.75":"$25.8","40.5":"$40.5","55.25":"$55.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$69.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,25.75,40.5,55.25,70],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.03,51.48923076923077,52.94846153846154,54.40769230769231,55.86692307692308,57.326153846153844,58.785384615384615,60.244615384615386,61.70384615384616,63.16307692307692,64.62230769230769,66.08153846153846,67.54076923076923,{"y":69,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.03,49.03846153846154,48.04692307692308,47.05538461538462,46.06384615384616,45.072307692307696,44.080769230769235,43.08923076923077,42.097692307692306,41.106153846153845,40.114615384615384,39.12307692307692,38.13153846153846,{"y":37.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.03,47.104615384615386,44.17923076923077,41.253846153846155,38.32846153846154,35.403076923076924,32.47769230769231,29.552307692307693,26.626923076923077,23.701538461538462,20.776153846153846,17.85076923076923,14.925384615384615,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.16,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.03,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.69,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.605,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.19,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 75, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 92, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":24.16,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 95, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.49,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 101, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":42.55,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 117, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":52.845,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 131, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":50.03,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 79, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$69.00

Average Price Target$37.14

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Courtney Breen

Bernstein

―

Hold

―

Reiterated

04/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (NASDAQ: RCKT) and Moderna (NASDAQ: MRNA)

Eliana Merle

Barclays

$25→$48

Hold

-2.44%

Downside

Assigned

04/01/26

Moderna price target raised to $48 from $25 at BarclaysModerna price target raised to $48 from $25 at Barclays

Salveen Richter

Goldman Sachs

$41

Hold

-16.67%

Downside

Reiterated

03/31/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Palisade Bio (NASDAQ: PALI) and Moderna (NASDAQ: MRNA)

Alec Stranahan

Bank of America Securities

$31

Sell

-36.99%

Downside

Reiterated

03/24/26

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Xencor (NASDAQ: XNCR)

Cory Kasimov

Evercore ISI

$35

Hold

-28.86%

Downside

Reiterated

03/04/26

Moderna (MRNA) Receives a Hold from Evercore ISI

Myles Minter

William Blair

―

Hold

―

Reiterated

03/03/26

Moderna: Litigation Relief Supports Oncology Pipeline, But Legal Overhang Keeps Risk‑Reward Balanced at Hold

Geoff Meacham

Citi

$41

Hold

-16.67%

Downside

Reiterated

03/03/26

Moderna: Legal Overhang Eased but Valuation, Cash Headwinds and Respiratory Concentration Justify Neutral Stance

Edward Tenthoff

Piper Sandler

$69

Buy

40.24%

Upside

Reiterated

03/02/26

Analysts Are Bullish on These Healthcare Stocks: Nyxoah (NYXH), Moderna (MRNA)

Terence Flynn

Morgan Stanley

$30

Hold

-39.02%

Downside

Reiterated

02/23/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Tyler Van Buren

TD Cowen

$40

Hold

-18.70%

Downside

Reiterated

02/20/26

Moderna: Balanced Pipeline Upside and Execution Risks Support Continued Hold Rating

Luca Issi

RBC Capital

$25→$30

Hold

-39.02%

Downside

Reiterated

02/17/26

Moderna price target raised to $30 from $25 at RBC CapitalModerna price target raised to $30 from $25 at RBC Capital

Michael Yee

UBS

$34→$36

Hold

-26.83%

Downside

Reiterated

02/16/26

Moderna price target raised to $36 from $34 at UBSModerna price target raised to $36 from $34 at UBS

Joseph Stringer

Needham

―

Hold

―

Reiterated

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Avantor (NYSE: AVTR) and Moderna (NASDAQ: MRNA)

Andrew Tsai

Jefferies

$30

Hold

-39.02%

Downside

Reiterated

02/11/26

Jefferies Sticks to Its Hold Rating for Moderna (MRNA)

Mani Foroohar

Leerink Partners

$17→$12

Sell

-75.61%

Downside

Reiterated

02/11/26

Regulatory Setback in Moderna’s Flu Franchise Drives Lowered Probabilities of Success, Heightened Risk, and a Cut to $12 Price Target

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Courtney Breen

Bernstein

―

Hold

―

Reiterated

04/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (NASDAQ: RCKT) and Moderna (NASDAQ: MRNA)

Eliana Merle

Barclays

$25→$48

Hold

-2.44%

Downside

Assigned

04/01/26

Moderna price target raised to $48 from $25 at BarclaysModerna price target raised to $48 from $25 at Barclays

Salveen Richter

Goldman Sachs

$41

Hold

-16.67%

Downside

Reiterated

03/31/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Palisade Bio (NASDAQ: PALI) and Moderna (NASDAQ: MRNA)

Alec Stranahan

Bank of America Securities

$31

Sell

-36.99%

Downside

Reiterated

03/24/26

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Xencor (NASDAQ: XNCR)

Cory Kasimov

Evercore ISI

$35

Hold

-28.86%

Downside

Reiterated

03/04/26

Moderna (MRNA) Receives a Hold from Evercore ISI

Myles Minter

William Blair

―

Hold

―

Reiterated

03/03/26

Moderna: Litigation Relief Supports Oncology Pipeline, But Legal Overhang Keeps Risk‑Reward Balanced at Hold

Geoff Meacham

Citi

$41

Hold

-16.67%

Downside

Reiterated

03/03/26

Moderna: Legal Overhang Eased but Valuation, Cash Headwinds and Respiratory Concentration Justify Neutral Stance

Edward Tenthoff

Piper Sandler

$69

Buy

40.24%

Upside

Reiterated

03/02/26

Analysts Are Bullish on These Healthcare Stocks: Nyxoah (NYXH), Moderna (MRNA)

Terence Flynn

Morgan Stanley

$30

Hold

-39.02%

Downside

Reiterated

02/23/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Tyler Van Buren

TD Cowen

$40

Hold

-18.70%

Downside

Reiterated

02/20/26

Moderna: Balanced Pipeline Upside and Execution Risks Support Continued Hold Rating

Luca Issi

RBC Capital

$25→$30

Hold

-39.02%

Downside

Reiterated

02/17/26

Moderna price target raised to $30 from $25 at RBC CapitalModerna price target raised to $30 from $25 at RBC Capital

Michael Yee

UBS

$34→$36

Hold

-26.83%

Downside

Reiterated

02/16/26

Moderna price target raised to $36 from $34 at UBSModerna price target raised to $36 from $34 at UBS

Joseph Stringer

Needham

―

Hold

―

Reiterated

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Avantor (NYSE: AVTR) and Moderna (NASDAQ: MRNA)

Andrew Tsai

Jefferies

$30

Hold

-39.02%

Downside

Reiterated

02/11/26

Jefferies Sticks to Its Hold Rating for Moderna (MRNA)

Mani Foroohar

Leerink Partners

$17→$12

Sell

-75.61%

Downside

Reiterated

02/11/26

Regulatory Setback in Moderna’s Flu Franchise Drives Lowered Probabilities of Success, Heightened Risk, and a Cut to $12 Price Target

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

3 Months

xxx

Success Rate

29/49 ratings generated profit

Average Return

-10.13%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 59.18% of your transactions generating a profit, with an average return of -10.13% per trade.

1 Year

Mani ForooharLeerink Partners

Success Rate

32/49 ratings generated profit

Average Return

-16.97%

reiterated a sell rating 2 months ago

Copying Mani Foroohar's trades and holding each position for 1 Year would result in 65.31% of your transactions generating a profit, with an average return of -16.97% per trade.

2 Years

xxx

Success Rate

35/49 ratings generated profit

Average Return

+7.86%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +7.86% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRNA Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

101

117

131

Sell

Strong Sell

total

113

119

132

147

In the current month, MRNA has received 3 Buy Ratings, 79 Hold Ratings, and 6 Sell Ratings. MRNA average Analyst price target in the past 3 months is 37.14.

Each month's total comprises the sum of three months' worth of ratings.

MRNA Financial Forecast

MRNA Earnings Forecast

Next quarter’s earnings estimate for MRNA is -$2.18 with a range of -$4.29 to -$1.65. The previous quarter’s EPS was -$2.11. MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MRNA has Performed in-line its overall industry.

MRNA Sales Forecast

Next quarter’s sales forecast for MRNA is $239.70M with a range of $63.00M to $383.90M. The previous quarter’s sales results were $678.00M. MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MRNA has Performed in-line its overall industry.

MRNA Stock Forecast FAQ

What is MRNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Moderna’s 12-month average price target is 37.14.

What is MRNA’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MRNA, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRNA a Buy, Sell or Hold?

Moderna has a consensus rating of Hold which is based on 1 buy ratings, 15 hold ratings and 2 sell ratings.

What is Moderna’s price target?

The average price target for Moderna is 37.14. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $69.00 ,the lowest forecast is $12.00. The average price target represents -24.51% Decrease from the current price of $49.2.

What do analysts say about Moderna?

Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of MRNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Moderna (MRNA) Stock Forecast & Price Target

MRNA Analyst Ratings

MRNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Moderna

MRNA Analyst Recommendation Trends

MRNA Financial Forecast

MRNA Earnings Forecast

MRNA Sales Forecast

MRNA Stock Forecast FAQ

Detailed List of Analyst Forecasts